BREAST CYTOPATHOLOGY

Index 169
ductal carcinoma in situ, 91
fibrocystic changes, 21
gynecomastia, 50
hamartoma, 83
intraductal papilloma, 73
invasive ductal carcinoma
not otherwise specified
(NOS), 96
invasive micropapillary
carcinoma, 107
lactation-related breast
changes, 46
metaplastic carcinoma,
126
phyllodes tumors, 63, 67
proliferative breast disease,
25
pseudoangiomatous
stromal hyperplasia, 54
tubular carcinoma, 60, 113
as “gray zone diagnosis”
cause, 27, 28
hypercellularity of, 58, 59
juvenile, 62
misdiagnosis of, 3
mucin in, 62
myoepithelial cells in, 11, 59,
60, 61
with myxoid change, 108
Fibrocystic breast changes,
19–21
clinical features of, 19
columnar cell lesions
associated with, 28
cytomorphologic
characteristics of, 19–21
differential diagnoses of
carcinoma with
osteoclastic-type giant
cells, 128
fibroadenoma, 62
granular cell tumors, 75
hamartoma, 83
lipomas, 78
myofibroblastoma, 79
secretory carcinoma, 116
mucoceles associated with, 36
proliferative breast diseaserelated,
25
Fibrolipoma, 78
Fibromatosis, differentiated
from
inflammatory myofibroblastic
tumors, 52
metaplastic carcinoma, 127
Fine-needle aspirates
cytologic criteria for, 12
from normal breast, 12
on-site assessment of, 4
Fine-needle aspiration, of the
breast
adequacy of, 5
statement of, 7
advantages of, 8
clinical indications for, 8
complications of, 5, 9
contraindications to, 5
diagnostic pitfalls in, 7, 8–9
diagnostic sensitivity and
specificity of, 2
as dual diagnostic and
treatment tool, 5
false-negative/false-positive
findings in, 2–3
“gray zone diagnosis” in, 1–2,
27–28
apocrine carcinoma, 123
benign sources of, 27
malignant sources of, 28
as initial diagnostic modality,
1–2
limitations of, 7, 9
in males, 49, 50
“nondiagnostic,” 3